VALNEVA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.248 EUR | -0.18% |
|
-4.02% | -31.27% |
| 05-07 | Valneva SE Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 05-07 | Transcript : Valneva SE, Q1 2024 Earnings Call, May 07, 2024 |
Presenter SpeechRobert Yedid (Attendees)Welcome. If I can get everybody's attention, my name i...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The group takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.
Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets two proprietary travel vaccines as well as certain third-party vaccines leveraging its established commercial infrastructure.
Revenues from its growing commercial business help fuel the continued advancement of Valneva's vaccine pipeline. This includes the world's first vaccine against the chikungunya virus and the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.
Calendar
25/06/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.254
EUR
Average target price
8.967
EUR
Spread / Average Target
+175.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -31.27% | 485M | |
| +25.29% | 46.71B | |
| +48.83% | 41.8B | |
| -1.18% | 41.52B | |
| -3.42% | 29.55B | |
| +10.30% | 25.78B | |
| -20.75% | 19.26B | |
| +0.67% | 12.14B | |
| -1.15% | 12.08B | |
| +26.72% | 11.98B |
- Stock Market
- Equities
- VLA Stock
- News Valneva
- Transcript : Valneva SE - Analyst/Investor Day
